An Indian Multicentric Open Label Prospective Post Marketing Surveillance Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 19 Jul 2019
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Roche
- 12 Nov 2018 Status changed from not yet recruiting to recruiting.
- 19 Oct 2018 Planned End Date changed from 30 Nov 2021 to 30 Nov 2020.
- 19 Oct 2018 Planned primary completion date changed from 30 Nov 2021 to 30 Nov 2020.